Cem Yalaza

Cem Yalaza

Auto-generated profile, based on publicly available information

Cem Yalaza

Department of Biochemistry, Faculty of Pharmacy, Başkent University, 06790 Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2018 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
SGSevda Guzel
Sevda Guzel
NCNecmiye Canacankatan
Necmiye Canacankatan
CYCem Yalaza
Cem Yalaza
DKDeniz Kibar
Deniz Kibar
BYBanu Coskun Yilmaz
Banu Coskun Yilmaz
Vancomycin (VCM), a glycopeptide antibiotic, is a drug widely used in severe infections. However, VCM induce notable nephrotoxic side effects. Naringenin (NAR) is a natural of flavonoid and are known as strongly antioxidant, nefroprotective, antiapoptotic, and anti-inflammatory. The purpose of this study was to determine the potential protective effects of NAR against VCM-induced nephrotoxicity by measuring apoptotic and oxidative stress markers and evaluating histopathological alterations in rats. For this purpose, we used male Wistar albino rats that divided into seven groups: (i) Control [saline, intraperitoneally (i.p.)], (ii) carboxymethyl cellulose (0.5% CMC, orally), (iii) VCM (400 mg/kg, i.p.), (iv) NAR100 (100 mg/kg, orally), (v) VCM + NAR25 (25 mg/kg, orally), (vi) VCM + NAR50 (50 mg/kg, orally), and (vii) VCM + NAR100 (100 mg/kg, orally) groups. VCM administration was started one day after the first treatment of NAR and continued across 7-day. Caspase-3, -8, and-9 activities and malondialdehyde (MDA) and nitric oxide (NO) levels were measured by colorimetric methods in the kidney tissues, creatinine, and blood urea nitrogen (BUN) levels were analyzed based on ELISA in serum. Caspase-3 and -8 activities, NO levels, serum creatinine and BUN levels were significantly higher in VCM group in comparison with VCM + NAR (25, 50, and 100) groups (p < 0.05). Caspase-9 activity and MDA were significantly higher in VCM group compared to VCM + NAR (25 and 50) groups (p < 0.05). Histopathological alterations in VCM group were significantly diminished by administration of NAR, especially NAR 25. In conclusion, NAR 25 and 50 mg have more potent protective effects on VCM-induced nephrotoxicity compared to NAR 100 mg.

1 May 2017
Verified
Journal Article
Closed access
CYCem Yalaza
Cem Yalaza
HAHandan Ak
Handan Ak
MCMehmet Sedat Cagli
Mehmet Sedat Cagli
EOErkin Ozgiray
Erkin Ozgiray
SASevcan Atay
Sevcan Atay
HAHikmet Hakan Aydin
Hikmet Hakan Aydin

12 August 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
CYCem Yalaza
Cem Yalaza
NCNecmiye Canacankatan
Necmiye Canacankatan
IGİcLal Gürses
İcLal Gürses
HAHakan Aytan
Hakan Aytan
BTBahar Taşdelen
Bahar Taşdelen

16 June 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CYCem Yalaza
Cem Yalaza
ŞAŞerife Efsun ANTMEN
Şerife Efsun ANTMEN
SASaliha Ece Acuner
Saliha Ece Acuner
HÖHasan ÖZ
Hasan ÖZ
EBEcem Bulut
Ecem Bulut
NCNecmiye Canacankatan
Necmiye Canacankatan
Human epidermal growth factor receptor-2 (HER2) is a tyrosine kinase receptor involved in cell growth and differentiation. Targeting HER2 is a critical strategy in HER2-positive breast cancer treatment. Despite advancements in HER2-targeted therapies, drug resistance and side effects remain significant challenges. Therefore, identifying novel HER2 inhibitors with the potential to overcome resistance mechanisms while maintaining favorable drug-like properties is essential. Identifying novel HER2 inhibitors with high binding affinity and favorable drug-like properties is essential for overcoming these limitations. This study employed molecular docking and molecular dynamics simulations to evaluate the binding potential of plant-derived and synthetic compounds against HER2. The most promising candidates were further analyzed using ADMET profiling and binding free energy calculations to assess their drug-likeness and binding free energy. Among the tested compounds, axitinib, prunetin, and silymarin demonstrated strong HER2-binding affinities comparable to established inhibitors such as TAK-285 and lapatinib. Molecular dynamics simulations revealed that prunetin formed the most stable HER2-ligand complex, while axitinib exhibited the lowest binding free energy, indicating a strong interaction potential. ADMET analysis confirmed axitinib and prunetin as favorable drug candidates, whereas silymarin exhibited lower intestinal absorption. In conclusion, axitinib and prunetin emerged as promising HER2 inhibitors that may offer therapeutic advantages by addressing both drug resistance and toxicity concerns in HER2-positive breast cancer treatment. Prunetin, with its lower toxicity and higher stability, presents a safer therapeutic option, whereas axitinib offers high binding affinity. These findings suggest that these compounds could help overcome resistance and side effects associated with current HER2-targeted therapies.

30 June 2021 in Clinical and Experimental Health Sciences
Verified
Journal Article
Closed access
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
SGSevda Güzel
Sevda Güzel
NCNecmiye Canacankatan
Necmiye Canacankatan
CYCem Yalaza
Cem Yalaza
DKDeniz Ki̇bAr
Deniz Ki̇bAr
GBGulsen Bayrak
Gulsen Bayrak
Objective: This investigation aimed to detect the possible protective impacts of naringenin (NAR) on vancomycin (VCM)-induced liver toxicity through measuring caspase-3, -8 and -9 activities as markers of apoptosis and the levels of tumor necrosis factor-alpha, cyclooxygenase-2 and vascular endothelial growth factor as inflammation markers and assessing the histopathological alterations in rats. Methods: The rats were allocated into seven groups as, the control group (saline, intraperitoneally (i.p.)), VCM group (400 mg/kg/day, i.p.), Carboxymethyl cellulose group (0.5% CMC, orally), NAR100 group (100 mg/kg/day, orally), VCM+NAR25 group (25 mg/kg/day, orally), VCM+NAR50 group (50 mg/kg/day, orally), VCM+NAR100 group (100 mg/kg/day, orally). The caspase enzyme activities and inflammation markers were measured using colorimetric methods and ELISA, respectively. Histopathological examinations were performed. Results: The caspase activities and levels of inflammation markers were significantly higher in the VCM group as opposed to the other groups. The caspase activities were significantly ameliorated in the VCM+NAR25 group compared to the VCM+NAR50 and VCM+NAR100 groups, but the levels of inflammation markers were significantly attenuated in VCM+NAR50 group and, especially, VCM+NAR100 group compared to VCM+NAR25 group. Conclusion: NAR has potential protective impact on liver injury caused by VCM, and the protective impacts of NAR at distinct doses may occur via different molecular mechanisms.

15 September 2025 in Archives of Medical Science
Verified
Journal Article
Open access
ŞAŞerife Efsun ANTMEN
Şerife Efsun ANTMEN
CYCem Yalaza
Cem Yalaza
FTFerah Tuncel
Ferah Tuncel
Mustafa BerkeşoğluMustafa Berkeşoğlu
Mustafa Berkeşoğlu
SESema Erden Erturk
Sema Erden Erturk
NCNecmiye Canacankatan
Necmiye Canacankatan
Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Ferroptosis, a regulated form of cell death driven by lipid peroxidation, has emerged as a potential therapeutic target. This study aimed to evaluate the expression levels of ferroptosis-associated genes GPX4, ACSL4, and BCAT2 in TNBC tissues and to investigate their potential as diagnostic or therapeutic biomarkers.Material and methods: A total of 100 formalin-fixed paraffin-embedded (FFPE) breast tissue samples were analyzed, including 60 TNBC patient samples and 40 healthy controls. Gene expression levels of GPX4, ACSL4, and BCAT2 were determined using RT-qPCR. Statistical comparisons were conducted using the Mann–Whitney U test, and correlation analyses were performed using Spearman’s test.Results: The expression levels of GPX4, ACSL4, and BCAT2 were significantly decreased in the TNBC group compared to controls (p = 0.0001 for all genes). Strong positive correlations were observed among the three genes, with BCAT2 showing the highest correlation with both GPX4 (R=0.636) and ACSL4 (R=0.683). Additionally, BCAT2 expression negatively correlated with tumor diameter and Ki-67 index.Conclusions: The significant downregulation and strong positive correlation of GPX4, ACSL4, and BCAT2 in TNBC tissues suggest a coordinated suppression of ferroptosis. These findings highlight the potential of targeting ferroptosis as a novel therapeutic strategy in TNBC and propose these genes as candidate biomarkers for diagnosis and treatment response.